Sinew Pharma (6634) to Present Latest SNP-6 Data at 9th Annual MASH Drug Development Summit in Boston (USA).
For the second consecutive year, Sinew Pharma (6634) has been invited to deliver an oral presentation on the opening day of the 9th Annual MASH Drug Development Summit in Boston (USA), where it will unveil the latest results from its investigational therapy SNP-6 and associated non-invasive biomarkers for metabolic dysfunction-associated steatohepatitis (MASH). The summit, to be held from September 29 to October 1, will bring together leading global medical experts, senior pharmaceutical executives, and academic researchers to discuss advances and innovative therapies in MASH. At the meeting, Sinew Pharma will present safety and efficacy data from its multi-target candidate SNP-6, including findings on multiple non-invasive biomarkers for assessing MASH severity—underscoring the company’s R&D strength in MASH therapeutics.
Notably, the summit will feature an impressive lineup of international pharmaceutical companies, including Madrigal (the first to bring a MASH drug to market), Roche, AstraZeneca, Merck, Pfizer, Eli Lilly, and Bristol Myers Squibb, all of which are expected to send senior executives to participate. This reflects the growing international recognition and attention toward Sinew Pharma’s research achievements.
Sinew Pharma Chairman and CEO Kai-Min Chu stated:
“We are honored to have the opportunity to share our latest research results on this international platform and to engage with global leaders on the future of MASH treatment. This represents not only an important milestone in advancing our R&D efforts, but also a key opportunity to foster international collaborations and potential licensing partnerships.”
